GenMark Diagnostics has inked a non-exclusive licensing deal with PerkinElmer for its microfluidics patent portfolio. Financial terms of the deal were not revealed.
The President of Life Sciences and Technology at PerkinElmer, Kevin Hrusovsky stated that the utilization of microfluidics in multiplex molecular tests is an important enabling platform for custom-made health research. Through non-exclusive license deals, like the one signed with GenMark, the company continues to strengthen its extensive portfolio of microfluidics in order to expand its market presence and generate sales opportunities in markets and applications that match its direct channel products.
The President and Chief Executive Officer at GenMark Diagnostics, Hany Massarany commented that this licensing deal with PerkinElmer reinforces the patent portfolio of GenMark Diagnostics while the company widens its portfolio of high-value multiplex molecular tests and design new advanced platforms that will provide better performance to customers across the globe.
GenMark Diagnostics provides automated, multiplex molecular diagnostic testing systems to identify and measure RNA and DNA targets to detect disease and improve patient treatment. The company’s eSensor XT-8 system is compatible with a number of molecular diagnostic tests as it features self-sufficient, disposable test cartridges, a user-friendly workstation, and a proprietary eSensor detection technology. At present, the company offers three FDA-approved tests, namely Thrombophilia Risk Test, Warfarin Sensitivity Test and Cystic Fibrosis Genotyping Test.
PerkinElmer provides solutions for enhancing the health and safety of the environment and people.
Source: http://www.genmarkdx.com/